BR112019023260A2 - Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos - Google Patents

Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos

Info

Publication number
BR112019023260A2
BR112019023260A2 BR112019023260-5A BR112019023260A BR112019023260A2 BR 112019023260 A2 BR112019023260 A2 BR 112019023260A2 BR 112019023260 A BR112019023260 A BR 112019023260A BR 112019023260 A2 BR112019023260 A2 BR 112019023260A2
Authority
BR
Brazil
Prior art keywords
fibroblast growth
growth factors
modified
therapeutic uses
modified recombinant
Prior art date
Application number
BR112019023260-5A
Other languages
English (en)
Inventor
Eveleth David
Jenkins-Eveleth Jennifer
Subramaniam Amuthakannan
Bradshaw Ralph
Original Assignee
Trefoil Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trefoil Therapeutics, Inc. filed Critical Trefoil Therapeutics, Inc.
Publication of BR112019023260A2 publication Critical patent/BR112019023260A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

polipeptídeo relacionado a fatores de crescimento de fibroblastos recombinantes modificados, composição e seus usos. são descritos na presente invenção polipeptídeos de fator de crescimento de fibroblastos modificados (fgf), composições farmacêuticas e medicamentos que incluem esses polipeptídeos de fgf modificados, e métodos de uso desses polipeptídeos de fgf modificados para tratar ou prevenir condições que se beneficiam da administração de fgfs.
BR112019023260-5A 2017-05-05 2018-05-04 Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos BR112019023260A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762502540P 2017-05-05 2017-05-05
US201762502529P 2017-05-05 2017-05-05
US62/502,529 2017-05-05
US62/502,540 2017-05-05
US201762584624P 2017-11-10 2017-11-10
US62/584,624 2017-11-10
PCT/US2018/031189 WO2018204847A2 (en) 2017-05-05 2018-05-04 Recombinant modified fibroblast growth factors and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
BR112019023260A2 true BR112019023260A2 (pt) 2022-02-22

Family

ID=64016756

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019023260-5A BR112019023260A2 (pt) 2017-05-05 2018-05-04 Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos

Country Status (10)

Country Link
US (2) US11479591B2 (pt)
EP (1) EP3619324A4 (pt)
JP (1) JP2020518287A (pt)
KR (1) KR20200078425A (pt)
CN (1) CN111148755A (pt)
AU (1) AU2018261021A1 (pt)
BR (1) BR112019023260A2 (pt)
CA (1) CA3062473A1 (pt)
MX (1) MX2019013210A (pt)
WO (1) WO2018204847A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3619324A4 (en) 2017-05-05 2020-12-30 Trefoil Therapeutics, Inc. RECOMBINATED MODIFIED FIBROBLASTIC GROWTH FACTORS AND THEIR THERAPEUTIC USES
EP4174058A1 (en) 2020-06-26 2023-05-03 LT Materials Co., Ltd. Heterocyclic compound and organic light-emitting device using same
EP4337243A1 (en) * 2021-05-14 2024-03-20 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease
CN113289005B (zh) * 2021-07-06 2022-05-31 温州医科大学 rhFGF-21在制备治疗干眼症药物中的应用
WO2023019218A1 (en) * 2021-08-12 2023-02-16 Trefoil Therapeutics, Inc. Modified fibroblast growth factors for treating fibrotic diseases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552528A (en) 1986-03-03 1996-09-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bovine b-endothelial cell growth factor
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
GB2223496B (en) 1988-08-08 1992-05-27 British Bio Technology Synthetic gene encoding mature human acid fibroblast growth factor
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
GB9523946D0 (en) 1995-11-23 1996-01-24 Bayer Ag Leukotriene antagonistic benzoic acid derivatives
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
WO2001038357A2 (en) 1999-11-22 2001-05-31 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
WO2002014471A2 (en) * 2000-08-15 2002-02-21 Phage Biotechnology Corporation A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
US20050227929A1 (en) 2003-11-13 2005-10-13 Masferrer Jaime L Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
US7790682B1 (en) 2003-12-02 2010-09-07 The Florida State University Research Foundation, Inc. Engineered human acidic fibroblast growth factors and associated methods
EA200601121A1 (ru) 2003-12-10 2006-10-27 Эли Лилли Энд Компани Мутеины фактора роста фибробластов 21
US7776825B1 (en) 2006-11-09 2010-08-17 Florida State University Research Foundation, Incorporated Mutant polypeptides of fibroblast growth factor 1
US7659379B1 (en) 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
ES2539124T3 (es) * 2008-01-22 2015-06-26 Araim Pharmaceuticals, Inc. Péptidos y análogos peptídicos protectores de tejido para la prevención y el tratamiento de enfermedades y trastornos asociados con daño tisular
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
US20110224404A1 (en) 2010-03-11 2011-09-15 Florida State University Research Foundation Method for development of a peptide building block useful for de novo protein design
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
US20150253308A1 (en) * 2013-05-03 2015-09-10 Orasis Compositions and methods of treating glaucoma
DK3049100T3 (da) 2013-09-25 2020-03-02 Trefoil Therapeutics Llc Modificerede fibroblastvækstfaktorer-1 til behandling af øjenlidelser
EP3060238A4 (en) 2013-10-21 2017-06-07 Salk Institute for Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
WO2015198175A1 (en) 2014-06-27 2015-12-30 Florida State University Research Foundation, Inc. Design of fgf-1 mutants to effectively eliminate reactive cysteine residues
AU2016252426A1 (en) 2015-04-20 2017-11-23 Salk Institute For Biological Studies Fibroblast growth factor (FGF) 1 mutants and methods of use to reduce blood glucose
AU2016252423A1 (en) 2015-04-20 2017-11-23 Florida State University Research Foundation, Incorporated Fibroblast growth factor (FGF) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose
JP6559239B2 (ja) 2015-08-13 2019-08-14 富士フイルム株式会社 多能性幹細胞の培養方法、培養容器の製造方法、培養容器、及び細胞培養用の足場材料
EP3619324A4 (en) 2017-05-05 2020-12-30 Trefoil Therapeutics, Inc. RECOMBINATED MODIFIED FIBROBLASTIC GROWTH FACTORS AND THEIR THERAPEUTIC USES

Also Published As

Publication number Publication date
CA3062473A1 (en) 2018-11-08
AU2018261021A1 (en) 2019-12-12
RU2019139358A (ru) 2021-06-07
EP3619324A4 (en) 2020-12-30
KR20200078425A (ko) 2020-07-01
US20230130851A1 (en) 2023-04-27
WO2018204847A2 (en) 2018-11-08
RU2019139358A3 (pt) 2021-08-26
MX2019013210A (es) 2020-07-20
US11479591B2 (en) 2022-10-25
US20200190158A1 (en) 2020-06-18
JP2020518287A (ja) 2020-06-25
CN111148755A (zh) 2020-05-12
EP3619324A2 (en) 2020-03-11

Similar Documents

Publication Publication Date Title
BR112019023260A2 (pt) Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos
BR112019000528A2 (pt) distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
ECSP14030742A (es) Proteínas del factor 21 de crecimiento del fibroblasto
BR112018001761A2 (pt) uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
BR112018071200A2 (pt) terapia genética para o tratamento da hemofilia a
BR112015032875A2 (pt) derivados de peptídeos do tipo glp-1, e usos dos mesmos
BR112021018506A2 (pt) Terapia de combinação para tratamento do câncer
BR112017019062A2 (pt) conjugados de anticorpo-fármaco (adc) que se ligam a proteínas flt3
BR112016015660A2 (pt) formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg)
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
BR112019017393A8 (pt) Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112021006280A2 (pt) terapias imunoablativas
CR20180184A (es) Compuestos heteroarilo y su uso como fármacos terapéuticos
BR112023006024A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
CO2021013677A2 (es) Proceso para la fabricación de extractos bacterianos estables y su uso como fármacos
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
BR112018070819A2 (pt) peptídeos e composições farmacêuticas, nutracêuticas ou veterinárias para prevenção e/ou tratamento de queda de cabelo
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]